Prevention of Allosensitization

PreclinicalSmall molecule

Prevention of Allosensitization is one of 3 small molecule programs targeting Renal Transplant. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal TransplantNot yet recruiting

Renal TransplantPreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Renal Transplant

#DrugCompanyPhaseTrials

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 2

Clazakizumab

CSL Behring

Phase 2

1 3

Prevention of Allosensitization

UUniversity of British Columbia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Renal Transplant

NCT06802822

Clinical

Trials by Indication[1]

Renal Transplant1 trial

Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)

Not yet recruiting·UUniversity of British Columbia·N/A·NCT06802822·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prevention of Allosensitization. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prevention of Allosensitization compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prevention of Allosensitization. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of British Columbia

Prevention of Allosensitization

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Renal Transplant1 trial

References

Drug Info

Quick Facts

Related News